GSK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GSK is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has shown strong financial performance in its latest quarter and has a solid pipeline, the lack of significant positive trading signals, neutral technical indicators, and mixed analyst sentiment suggest waiting for a clearer entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 53.513, and moving averages are converging, showing no clear trend. Key support is at 51.877, and resistance is at 54.502. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Strong Q4 financial performance with revenue up 10.24% YoY, net income up 59.51% YoY, and EPS up 61.54% YoY.
Positive developments in the company's R&D pipeline, as highlighted by analyst commentary.
Settlement with Regeneron resolves legal uncertainty.
Recent news of Clover Biopharmaceuticals' RSV vaccine showing superior efficacy compared to GSK's AREXVY could impact market perception.
Mixed analyst ratings with several underweight and neutral ratings, citing mid-term growth challenges.
No significant hedge fund or insider trading activity, indicating a lack of strong institutional confidence.
In Q4 2025, GSK showed strong financial growth: Revenue increased by 10.24% YoY to $11.46 billion, net income rose by 59.51% YoY to $846 million, EPS increased by 61.54% YoY to $0.21, and gross margin improved by 1.12% YoY to 69.7%.
Analyst sentiment is mixed. While some firms raised price targets (e.g., TD Cowen to $70 and BofA to 2,350 GBp), others maintain underweight or neutral ratings, citing mid-term growth challenges and competitive pressures.
